Pharmacogenetics and immunosuppressive drugs in solid organ transplantation (Q38253383)

1 September 2017

1 reference

title

Pharmacogenetics and immunosuppressive drugs in solid organ transplantation (English)

1 reference

1 September 2017

organ transplantation

1 reference

1

Teun van Gelder

1 reference

1 September 2017

Ron H van Schaik

2

1 reference

PubMed ID

25247332

1 September 2017

Dennis A Hesselink

series ordinal

3

1 reference

PubMed ID

25247332

1 September 2017

language of work or name

English

0 references

publication date

23 September 2014

1 reference

Nature Reviews Nephrology

1 September 2017

1 reference

1 September 2017

10

1 reference

1 September 2017

725-731

1 reference

1 September 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2014.172

1 September 2017

0 references

cites work

Pharmacogenetics: from bench to byte--an update of guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Pharmacogenetic influences on mycophenolate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Target enzyme activity as a biomarker for immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Donor ABCB1 variant associates with increased risk for kidney allograft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Practicability of pharmacogenetics in transplantation medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Dosing equation for tacrolimus using genetic variants and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Validation of tacrolimus equation to predict troughs using genetic and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Development and use of active clinical decision support for preemptive pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 Data Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Therapeutic drug monitoring for mycophenolic acid is value for (little) money

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Pharmacodynamic monitoring of mycophenolate mofetil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The clinical benefits of cyclosporine C2-level monitoring: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

In vivo effects of interleukin-10 on human cytochrome P450 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.172

Long-term results of TPMT activity monitoring in azathioprine-treated renal allograft recipients

31 March 2020

1 reference

12 December 2020

Two distinct cDNAs for human IMP dehydrogenase

1 reference

12 December 2020

Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study.

1 reference

12 December 2020

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.

1 reference

12 December 2020

Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation

1 reference

12 December 2020

Optimization of initial tacrolimus dose using pharmacogenetic testing

1 reference

12 December 2020

AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.

1 reference

12 December 2020

Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2014.172

1 reference

1 September 2017

1 reference

PubMed ID

25247332